Jesper Wiklund has been appointed Chief Executive Officer of InDex Pharmaceuticals AB (InDex) as of September 1st, 2011. He will bring 17 years of international commercial experience in the…
Industrifonden invests MSEK 40 and becomes a new shareholder in InDex
Pharmaceuticals, which develops Kappaproct – a drug for treatment of severe
inflammatory bowel disease. Current shareholders, including SEB Venture Capital,
invest an additional MSEK 35. The financing will in large be used to conduct a clinical
phase III trial using Kappaproct with the aim of obtaining market approval.